| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 80.1 | 66.8 | 56.8 |
| Other income | 1.2 | 0.1 | 0.1 |
| Total income | 81.3 | 66.9 | 56.9 |
| Profit before exceptional items & tax | 14.2 | 13.1 | 10.0 |
| Profit before tax | 14.2 | 13.1 | 10.0 |
| Net profit | 10.5 | 10.0 | 7.7 |
| Operating margin | 17.5% | 19.6% | 17.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +36.40% |
|---|---|
| Net profit, quarter on quarter | +5.00% |
| Revenue, year on year | +41.00% |
NSE results filing, NSE: INFLUX. Figures extracted from the filing.
Influx Healthtech Ltd: key numbers
- Share price
- ₹281.45
- Market cap
- ₹651.6 Cr
- Revenue (annual)
- ₹146.8 Cr
- Net profit (annual)
- ₹20.54 Cr
- P/E (TTM)
- 31.7×Sector 50.4×
- Promoter holding
- 73.53%
- FII holding
- 0.16%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Influx Healthtech Ltd
All →Influx Healthtech Legal & Regulatory
NSE imposed a fine of Rs. 1.83 Lakhs on Influx Healthtech for a delay in submitting consolidated financial results for the half year ended March 31, 2026.
- Value
- ₹0.02 Cr
Influx Healthtech Annual General Meeting
Influx Healthtech Limited held its 6th Annual General Meeting on September 18, 2026. The company transacted the business items as per the AGM notice.
Influx Healthtech Other Announcement
Influx Healthtech dispatched letters to shareholders without registered emails with the FY 2025-26 Annual Report weblink and 6th AGM notice. The letters are sent under Regulation 36(1)(b) of the SEBI Listing Regulations.
Influx Healthtech Earnings Call: Key Takeaways
Influx Healthtech reported FY26 revenue of ₹146cr, a 41% YoY increase, with PAT at ₹20.5cr. Strategy focuses on scaling nutraceutical CDMO capacity by 2.5x through a new 75,000 sq ft facility.
Influx Healthtech Earnings Call: Key Takeaways
Influx Healthtech delivered strong 41% YoY revenue growth in H2 FY26, driven by nutraceuticals, despite margin pressure from aggressive hiring ahead of massive capacity expansion.
Influx Healthtech Earnings Call: Key Takeaways
Influx Healthtech delivered strong FY26 performance as a specialist CDMO in nutraceuticals and cosmetics, focusing on capacity expansion and new technology implementation following its 2025 NSE listing.